NYSE - Nasdaq Real Time Price USD

Abrdn Life Sciences Investors (HQL)

Compare
14.89 -0.24 (-1.56%)
As of 2:23 PM EDT. Market Open.
Loading Chart for HQL
DELL
  • Previous Close 15.13
  • Open 15.10
  • Bid 14.89 x 1000
  • Ask 14.91 x 1000
  • Day's Range 14.89 - 15.19
  • 52 Week Range 11.34 - 15.90
  • Volume 32,665
  • Avg. Volume 71,467
  • Market Cap (intraday) 407.358M
  • Beta (5Y Monthly) 0.70
  • PE Ratio (TTM) 11.11
  • EPS (TTM) 1.34
  • Earnings Date Dec 9, 2024 - Dec 13, 2024
  • Forward Dividend & Yield 1.96 (12.96%)
  • Ex-Dividend Date Aug 23, 2024
  • 1y Target Est --

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

--

Full Time Employees

September 30

Fiscal Year Ends

Recent News: HQL

View More

Performance Overview: HQL

Trailing total returns as of 10/23/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

HQL
21.63%
S&P 500
21.04%

1-Year Return

HQL
42.49%
S&P 500
36.67%

3-Year Return

HQL
3.92%
S&P 500
27.03%

5-Year Return

HQL
52.19%
S&P 500
92.70%

Compare To: HQL

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: HQL

View More

Valuation Measures

Annual
As of 10/21/2024
  • Market Cap

    413.54M

  • Enterprise Value

    --

  • Trailing P/E

    11.28

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    10.90

  • Price/Book (mrq)

    0.94

  • Enterprise Value/Revenue

    10.35

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    156.45%

  • Return on Assets (ttm)

    -0.32%

  • Return on Equity (ttm)

    1.28%

  • Revenue (ttm)

    3.51M

  • Net Income Avi to Common (ttm)

    5.5M

  • Diluted EPS (ttm)

    1.34

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: HQL

View More

Company Insights: HQL

Research Reports: HQL

View More

People Also Watch